1-3 of 3
Martin F. M. de Rooij
Close
Sort by
Journal Articles

Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy

Martin F. M. de Rooij, Annemieke Kuil, Arnon P. Kater, Marie José Kersten, Steven T. Pals, Marcel Spaargaren
Journal: Blood
Blood (2015) 125 (14): 2306–2309.
https://doi.org/10.1182/blood-2014-12-619163
Published: 2015
Includes: Supplemental data
Journal Articles

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, Laurence Elias
Journal: Blood
Blood (2013) 122 (14): 2412–2424.
https://doi.org/10.1182/blood-2013-02-482125
Published: 2013
Includes: Supplemental data
Journal Articles

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

Brief Report
Martin F. M. de Rooij, Annemieke Kuil, Christian R. Geest, Eric Eldering, Betty Y. Chang, Joseph J. Buggy, Steven T. Pals, Marcel Spaargaren
Journal: Blood
Blood (2012) 119 (11): 2590–2594.
https://doi.org/10.1182/blood-2011-11-390989
Published: 2012
Includes: Supplemental data